adempas 0.5mg comprimido recubierto
bayer s.a. - riociguat; - comprimido recubierto - por comprimido; riociguat 0.500000 mg; - riociguat
adempas 1.5mg comprimido recubierto
bayer s.a. - riociguat; - comprimido recubierto - por comprimido; riociguat 1.500000 mg; - riociguat
adempas 1mg comprimido recubierto
bayer s.a. - riociguat; - comprimido recubierto - por comprimido; riociguat 1.000000 mg; - riociguat
adempas 2.5mg comprimido recubierto
bayer s.a. - riociguat; - comprimido recubierto - por comprimido; riociguat 2.500000 mg; - riociguat
adempas 2mg comprimido recubierto
bayer s.a. - riociguat; - comprimido recubierto - por comprimido; riociguat 2.000000 mg; - riociguat
adempas
bayer ag - riociguat - hipertensión, pulmonar - antihipertensivos para la hipertensión arterial pulmonar - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. la eficacia se ha demostrado en un pah la población, incluyendo a las etiologías de la idiopático o hereditario hap o pah asociada con enfermedad del tejido conectivo. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.
adempas 1,0 mg comprimido
bayer - comprimido - riociguat 1 mg comprimido
adempas 1,5 mg comprimido
bayer - comprimido - riociguat 1,5 mg comprimido
adempas 2,0 mg comprimido
bayer - comprimido - riociguat 2 mg comprimido
adempas 2,5 mg comprimido
bayer - comprimido - riociguat 2,5 mg comprimido